查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585795

脑肿瘤药物市场：按治疗类型、适应症、分销管道划分 - 全球预测 2025-2030

Brain Cancer Drugs Market by Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Indication (Glioblastoma, Meningioma, Pituitary Tumors), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年脑肿瘤药物市场价值为20.3亿美元，预计到2024年将达到21.8亿美元，复合年增长率为7.43%，到2030年预计将达到33.5亿美元。

脑肿瘤治疗市场的范围包括脑肿瘤特异性治疗药物的市场开拓、生产和分销。这些包括化疗、标靶治疗、免疫疗法和支持性治疗药物，旨在治疗各种类型的脑肿瘤，如胶质母细胞瘤、星状细胞瘤和寡树突胶质瘤。脑肿瘤发生率的增加推动了对此类药物的需求，并且需要能够跨越血脑障壁并提供改进的疗效且副作用更少的创新治疗方法。这些药物主要用于医院、诊所和专门的癌症治疗中心，最终用户是医疗保健相关人员和需要客製化癌症治疗计划的患者。

主要市场统计
基准年[2023] 20.3亿美元
预测年份 [2024] 21.8亿美元
预测年份 [2030] 33.5亿美元
复合年增长率（%） 7.43%

市场成长受到医疗技术进步、研究经费增加以及对癌症早期检测意识提高等关键因素的影响。个人化医疗和次世代定序技术的出现为标靶治疗的发展提供了重大机会和成长潜力。製药公司和研究机构之间的合作正在为创新药物发现和临床试验打开大门。利用这些机会的主要建议包括投资于肿瘤基因和分子分析的药物研发，从而可以实现更精确的标靶和改善患者的治疗结果。

然而，这个市场也面临着高昂的开发和核准成本、严格的监管要求以及有效跨越血脑障壁的挑战等限制。另一个主要挑战是，有些脑肿瘤具有侵袭性、復发率高，通常对常规治疗方法有抵抗力。需要创新的领域包括开发有效针对肿瘤脉管系统和微环境的药物，以及奈米颗粒等新型输送系统，以增强药物向大脑的传递。市场的本质是高度动态和竞争的，需要相关人员不断创新和适应，以满足未满足的需求并克服现有的市场限制。

市场动态：揭示快速发展的脑肿瘤药物市场的关键市场洞察

供需的动态交互作用正在改变脑肿瘤药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 与久坐生活方式相关的脑肿瘤盛行率增加
    • 患有神经病变的老年人口迅速增加
    • 提高患者对治疗效果的认识
  • 市场限制因素
    • 使用标靶治疗抑制癌症生长
  • 市场机会
    • 政府和製药公司积极致力于药物研发
    • 使用奈米颗粒传输药物等领域取得了强劲进展
  • 市场挑战
    • 核准这些药物的严格监管指南

波特五力：驾驭脑瘤药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对脑肿瘤药物市场的影响

外部宏观环境因素在塑造脑肿瘤药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解脑肿瘤治疗药物市场的竞争状况

对脑肿瘤药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵脑瘤治疗市场供应商的绩效评估

FPNV定位矩阵是评估脑肿瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划脑肿瘤药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对脑肿瘤药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 久坐的生活方式导致脑肿瘤的发生率增加
      • 患有神经系统疾病的老年人口迅速增加
      • 提高患者对治疗可用性的认识
    • 抑制因素
      • 使用标靶治疗阻止癌症生长
    • 机会
      • 政府和製药公司对药物开发的有利方法
      • 使用奈米粒子传输药物等领域的强劲发展
    • 任务
      • 核准这些药物的严格监管指南
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的脑肿瘤药物市场

  • 化疗
  • 免疫疗法
  • 标靶治疗

第七章依适应症分類的脑肿瘤治疗药物市场

  • 神经胶母细胞瘤
  • 脑膜瘤
  • 脑下垂体瘤

第八章脑肿瘤药物市场：按分销管道

  • 医院药房
  • 零售药房

第九章美洲脑肿瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区脑肿瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲脑肿瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Antisense Therapeutics Limited
  • Aravive, Inc.
  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories
  • Elevar Therapeutics, Inc.
  • F. Hoffmann-La Roche AG
  • Fujifilm Corporation
  • GE Healthcare
  • Hitachi, Ltd.
  • Johnson & Johnson Services Inc.
  • Koninklijke Philips NV
  • Leadiant Biosciences, Inc.
  • Mankind Pharma Pvt. Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-434CCDA05263

The Brain Cancer Drugs Market was valued at USD 2.03 billion in 2023, expected to reach USD 2.18 billion in 2024, and is projected to grow at a CAGR of 7.43%, to USD 3.35 billion by 2030.

The scope of the market for brain cancer drugs encompasses the development, production, and distribution of therapeutic agents specifically targeting brain tumors. These include chemotherapy, targeted therapies, immunotherapy, and supportive care drugs aimed at treating different types of brain cancers like glioblastomas, astrocytomas, and oligodendrogliomas. The necessity for such drugs is driven by the increasing incidence of brain cancer, which requires innovative treatments that can penetrate the blood-brain barrier and offer improved efficacy with fewer side effects. The application of these drugs is mainly in hospitals, clinics, and specialized cancer treatment centers, with end-users consisting of medical professionals and patients requiring tailored cancer treatment plans.

KEY MARKET STATISTICS
Base Year [2023] USD 2.03 billion
Estimated Year [2024] USD 2.18 billion
Forecast Year [2030] USD 3.35 billion
CAGR (%) 7.43%

Market growth is influenced by key factors such as advancements in medical technology, increased research funding, and rising awareness of early cancer detection. The emergence of personalized medicine and next-generation sequencing technologies provide significant opportunities for developing targeted therapies, offering growth potential. Currently, collaborations between pharmaceutical companies and research institutions are opening doors for innovative drug discovery and clinical trials. A major recommendation to capitalize on these opportunities includes investing in R&D for drugs focusing on the genetic and molecular profiling of tumors, which can enable more precise targeting and improved patient outcomes.

However, the market also faces limitations from high developmental and approval costs, stringent regulatory requirements, and challenges in effectively crossing the blood-brain barrier. Another significant challenge is the aggressive nature of some brain tumors, which often leads to high relapse rates and resistance to conventional therapies. Areas ripe for innovation include the development of drugs that can effectively target tumor vasculature and microenvironment, and novel delivery systems such as nanoparticles to enhance drug delivery to the brain. The market's nature is highly dynamic and competitive, necessitating continuous innovation and adaptation by stakeholders to meet unmet patient needs and overcome existing market constraints.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Cancer Drugs Market

The Brain Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of brain cancer with sedentary lifestyles
    • Surge in geriatric population suffering from neurological disorders
    • Rising patient awareness on the availability of treatment
  • Market Restraints
    • Use of targeted therapies to block cancer growth
  • Market Opportunities
    • Favorable initiatives from government and pharmaceutical companies in the development of the drug
    • Robust development in areas such as use of nanoparticles to carry drugs
  • Market Challenges
    • Strict regulatory guidelines in the approval of these drugs

Porter's Five Forces: A Strategic Tool for Navigating the Brain Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Cancer Drugs Market

A detailed market share analysis in the Brain Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Cancer Drugs Market

A strategic analysis of the Brain Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Antisense Therapeutics Limited, Aravive, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Dr. Reddy's Laboratories, Elevar Therapeutics, Inc., F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi, Ltd., Johnson & Johnson Services Inc., Koninklijke Philips N.V., Leadiant Biosciences, Inc., Mankind Pharma Pvt. Ltd., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy.
  • Based on Indication, market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy and Retail pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of brain cancer with sedentary lifestyles
      • 5.1.1.2. Surge in geriatric population suffering from neurological disorders
      • 5.1.1.3. Rising patient awareness on the availability of treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Use of targeted therapies to block cancer growth
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable initiatives from government and pharmaceutical companies in the development of the drug
      • 5.1.3.2. Robust development in areas such as use of nanoparticles to carry drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory guidelines in the approval of these drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Cancer Drugs Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Targeted Therapy

7. Brain Cancer Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Glioblastoma
  • 7.3. Meningioma
  • 7.4. Pituitary Tumors

8. Brain Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Retail pharmacy

9. Americas Brain Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Brain Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Brain Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Antisense Therapeutics Limited
  • 2. Aravive, Inc.
  • 3. AstraZeneca PLC
  • 4. Bristol Myers Squibb Company
  • 5. Dr. Reddy's Laboratories
  • 6. Elevar Therapeutics, Inc.
  • 7. F. Hoffmann-La Roche AG
  • 8. Fujifilm Corporation
  • 9. GE Healthcare
  • 10. Hitachi, Ltd.
  • 11. Johnson & Johnson Services Inc.
  • 12. Koninklijke Philips N.V.
  • 13. Leadiant Biosciences, Inc.
  • 14. Mankind Pharma Pvt. Ltd.
  • 15. Merck & Co., Inc.
  • 16. Novartis International AG
  • 17. Pfizer, Inc.
  • 18. Siemens Healthineers AG
  • 19. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. BRAIN CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023